Work

A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.1026

Authors: Sara M. Tolaney, Dan G. Duda, Yves Boucher, Shom Goel, John Martin, Marek Ancukiewicz, Hannah Potler, Jaoa Incio, Jennifer A. Ligibel, Steven J. Isakoff, Dai Fukumura, Eric P. Winer, Ian E. Krop, Rakesh K. Jain

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Harvard University

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597772206

Cites:

Cited by: 14

Related to: 10